Pacylex Announces Orphan Drug Designation Granted to PCLX-001 for the Treatment of Acute Myeloid Leukemia

Pacylex today announced that the U.S. Food and Drug Administration (FDA) granted PCLX-001 Orphan Drug Designation for “treatment of patients with acute myeloid leukemia.” PCLX-001 is a first-in-class N-myristoylation inhibitor in clinical development by Pacylex. PCLX-001 is currently being studied in non-Hodgkin lymphoma (NHL) and solid tumor cancer patients at 4 sites in Canada. Pacylex has filed an IND to study PCLX-001 in the U.S. in AML patients.

Read the full story here.